PLANO, Texas, June 15, 2023 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) announced today that Joe Dziedzic, President and Chief Executive Officer, and Andrew Senn, Senior Vice President, Strategy, Business Development, and Investor Relations, will participate in Citi's 2023 European Healthcare Conference, which will be held at the Citigroup Centre, 33 Canada Square, London, England, beginning at 8:00 a.m. British Summer Time (3:00 a.m. Eastern Time), on Tuesday, June 20, 2023.
About Integer®
Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, vascular, portable medical and orthopedics markets. The Company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, the Company develops batteries for high-end niche applications in energy, military, and environmental markets. The Company's brands include Greatbatch Medical®, Lake Region Medical® and Electrochem®. Additional information is available at www.integer.net.
| Investor Relations: | Media Relations: |
| Andrew Senn | Kelly Butler |
| This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
| 763.951.8312 | 214.618.4216 |
| Last Trade: | US$119.54 |
| Daily Change: | -0.42 -0.35 |
| Daily Volume: | 99,605 |
| Market Cap: | US$4.170B |
July 10, 2025 April 24, 2025 April 24, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
